We are live on ! Find out more
KTTA icon

Pasithea Therapeutics

11 hedge funds and large institutions have $406K invested in Pasithea Therapeutics in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

22% more funds holding

Funds holding: 9 → 11 (+2)

0.91% less ownership

Funds ownership: 3.07% → 2.16% (-0.91%)

78% less capital inflows, than outflows

Capital inflows: $54.9K | Capital outflows: $251K

Holders
11
Holders Change
+2
Holders Change %
+22.22%
% of All Funds
0.18%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
4
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

KTTA Hedge Fund Activity: Q4 2022 in Review

11 of the 6,245 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics (KTTA) for Q4 2022, worth a combined $406K — down 61% from $1.03M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new KTTA positions and 1 closed out — a net gain of 2 holders — while 4 added to existing stakes and 2 trimmed.

The largest buyer was Virtu Financial, opening a new position worth an estimated $30.9K. The largest seller was K2 Principal Fund, cutting an estimated $209K.

  • 11 institutional investors held Pasithea Therapeutics (KTTA) as of Q4 2022, up from 9 in Q3 2022.
  • Funds reported $406K of Pasithea Therapeutics stock for Q4 2022, down 61% quarter-over-quarter.
  • 3 funds opened new Pasithea Therapeutics positions in Q4 2022 and 1 closed out, a net change of +2 holders.
  • The largest Pasithea Therapeutics buyer in Q4 2022 was Virtu Financial, an estimated $30.9K added.
  • The largest Pasithea Therapeutics seller in Q4 2022 was K2 Principal Fund, an estimated $209K sold.

Based on aggregated 13F filings for Q4 2022.